Buprenorphine transdermal - Samyang
Latest Information Update: 13 Jan 2022
At a glance
- Originator Samyang Group
- Class Cyclopropanes; Drug withdrawal therapies; Morphinans; Opioid analgesics; Small molecules
- Mechanism of Action Nociceptin receptor agonists; Opioid delta receptor agonists; Opioid kappa receptor antagonists; Opioid mu receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer pain; Postoperative pain
Most Recent Events
- 29 Nov 2005 Buprenorphine is available for licensing(http://www.samyangpharm.com)
- 29 Nov 2005 Phase-I clinical trials in Cancer pain in South Korea (Transdermal)
- 29 Nov 2005 Phase-I clinical trials in Postoperative pain in South Korea (Transdermal)